BioNTech SE has signed a share purchase agreement with Novartis AG, to acquire their GMP certified manufacturing facility in Marburg, Germany. The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational. The transaction is expected to close in the 4Q20. BioNTech plans to produce up to 250 million doses of BNT162b2 in 1H21, with the established team and drug substance and drug pr...